international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
Section 135 of the Securities and Exchanges Act, B.E. 2535 (1992) as amended by the Securities and Exchange Act (No. 2), B.E. 2542 (1999), the Office of the Securities and Exchange Commission hereby issues
Exchanges Act, B.E. 2535 (1992) as amended by the Securities and Exchange Act (No. 2), B.E. 2542 (1999), the Office of the Securities and Exchange Commission hereby issues the following regulations: Clause 1
permit by virtue of law, the Securities and Exchange Commission acting as the Capital Market Supervisory Board under Section 60 of the Securities and Exchange Act (No. 4) B.E. 2551 (2008) hereby issues the
market in the country last April. This caused problems for distribution channels of the Company’s customers, as they had to postpone their purchase orders of the Company’s products. As result, domestic
delay the purchase of raw materials in order to produce the products. The company is in the process of negotiating with the raw material suppliers and planning to solve the problems. For the three-month
the delay in the budget year 2020, which makes public investment "negative", as well as the drought problem, Thai Baht appreciation, the impact of the US trade war with China and Epidemic problems
with unexpected problems that occurred in the production process during 2019. Consequently, the production cost per unit has increased Selling Expenses Selling expenses for the fiscal year 2019 were in